{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T20:09:42Z","timestamp":1788120582408,"version":"build-2803163510"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"29","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Programme Hospitalier de Recherche Clinique","award":["PHRC 2015"],"award-info":[{"award-number":["PHRC 2015"]}]},{"name":"French Ministry of Health","award":["PHRC 15-0542"],"award-info":[{"award-number":["PHRC 15-0542"]}]},{"name":"Assistance Publique\u2014H\u00f4pitaux de Paris"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Aims<\/jats:title>\n                  <jats:p>This study aims to report the effects of \u03b2-blocker interruption on blood pressure (BP) and heart rate (HR) in the A\u03b2YSS trial where patients were randomized to interruption or continuation of \u03b2-blocker treatment after a myocardial infarction (MI).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Changes in HR and BP from baseline to post-randomization are reported using linear mixed repeated model, in the 3698 patients of the A\u03b2YSS trial with a median follow-up of 3.0 years. Additionally, changes in HR and BP and the impact on the primary endpoint (death, MI, stroke, hospitalization for cardiovascular reason) in the pre-specified subgroups of patients with or without history of hypertension were assessed using linear mixed repeated and adjusted Cox proportional hazards model, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>\u03b2-blocker interruption was associated with significant increase {least square mean difference [95% confidence interval (CI)]} in systolic BP [+3.7 (2.6, 4.8) mmHg, P &amp;lt; .001], diastolic BP [+3.3 (2.6, 4.0) mmHg, P &amp;lt; .001], and resting HR [+10 [9, 11) b.p.m., P &amp;lt; .001] at 6 months that persisted over the duration of follow-up despite an increase in antihypertensive drugs in the \u03b2-blocker interruption group. The effects were observed in both hypertensive (43% of the population) and non-hypertensive patients. Hypertensive patients were at higher risk of events (25.8% vs. 19.2%) as compared with patients without hypertension (adjusted hazard ratio 1.18, 95% CI 1.01\u20131.36, P = .03). Patients with hypertension had a particularly marked increase in the primary endpoint (risk difference 5.02%, 0.72%\u20139.32%, P = .014) when randomized to \u03b2-blocker interruption.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Interruption of \u03b2-blocker treatment after an uncomplicated MI led to a sustained increase in BP and HR, with potentially deleterious effects on outcomes, especially in patients with history of hypertension.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehaf170","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T05:16:34Z","timestamp":1747890994000},"page":"2894-2902","source":"Crossref","is-referenced-by-count":14,"title":["Beta-blocker interruption effects on blood pressure and heart rate after myocardial infarction: the A\u03b2YSS trial"],"prefix":"10.1093","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7700-0744","authenticated-orcid":false,"given":"Niki","family":"Procopi","sequence":"first","affiliation":[{"name":"Sorbonne Universit\u00e9, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re (AP-HP), ACTION Study Group, INSERM UMRS 1166, Institut de Cardiologie, 83 blvd de l'H\u00f4pital, 75013 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Zeitouni","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re (AP-HP), ACTION Study Group, INSERM UMRS 1166, Institut de Cardiologie, 83 blvd de l'H\u00f4pital, 75013 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7141-5209","authenticated-orcid":false,"given":"Mathieu","family":"Kerneis","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re (AP-HP), ACTION Study Group, INSERM UMRS 1166, Institut de Cardiologie, 83 blvd de l'H\u00f4pital, 75013 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Cayla","sequence":"additional","affiliation":[{"name":"ACTION Study Group, Cardiology Department, N\u00eemes University Hospital, Montpellier University , N\u00eemes ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8233-6039","authenticated-orcid":false,"given":"Emile","family":"Ferrari","sequence":"additional","affiliation":[{"name":"Service de Cardiologie, Universit\u00e9 C\u00f4te d'Azur, CHU de Nice, H\u00f4pital Pasteur 1 , Nice ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e9goire","family":"Range","sequence":"additional","affiliation":[{"name":"Service de Cardiologie, Centre Hospitalier de Chartres, H\u00f4pital Louis Pasteur , Le Coudray ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0533-9682","authenticated-orcid":false,"given":"Etienne","family":"Puymirat","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, H\u00f4pital Europ\u00e9en Georges-Pompidou, Universit\u00e9 Paris-Cit\u00e9 , Paris ,","place":["France"]},{"name":"Paris Cardiovascular Research Center, Inserm UMR_U970, Universit\u00e9 Paris-Cit\u00e9 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Delarche","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Centre Hospitalier de Pau , Pau ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Guedeney","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re (AP-HP), ACTION Study Group, INSERM UMRS 1166, Institut de Cardiologie, 83 blvd de l'H\u00f4pital, 75013 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzin","family":"Beygui","sequence":"additional","affiliation":[{"name":"Service de Cardiologie, CHU de Caen Normandie , 14000 Caen ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Desprets","sequence":"additional","affiliation":[{"name":"Service de Cardiologie, Centre Hospitalier de Cholet , Cholet ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4728-2220","authenticated-orcid":false,"given":"Jean-Louis","family":"Georges","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Centre Hospitalier de Versailles, Andr\u00e9 Mignot Hospital , Le Chesnay-Rocquencourt ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5889-7506","authenticated-orcid":false,"given":"Thomas","family":"Bochaton","sequence":"additional","affiliation":[{"name":"Intensive Cardiological Care Division, Hospices Civils de Lyon-H\u00f4pital Cardiovasculaire et Pulmonaire, Laboratoire CarMeN\u2013IRIS Team, INSERM, Universit\u00e9 Claude Bernard Lyon-1 , Bron ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Schiele","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Universit\u00e9 de Franche-Comt\u00e9, SINERGIES , Besan\u00e7on ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e9gory","family":"Ducrocq","sequence":"additional","affiliation":[{"name":"Cardiology Department, H\u00f4pital Bichat, AP-HP , 46 Rue Henri Huchard, 75018, Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Hauguel-Moreau","sequence":"additional","affiliation":[{"name":"ACTION Study Group, Department of Cardiology, Ambroise Par\u00e9 Hospital, Assistance Publique-H\u00f4pitaux de Paris (AP-HP), Universit\u00e9 de Versailles-Saint Quentin (UVSQ) , Boulogne-Billancourt ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphaelle","family":"Dumaine","sequence":"additional","affiliation":[{"name":"Les Grands Pr\u00e9s Cardiac Rehabilitation Department , 27 Rue Sainte-Christine, 77174 Villeneuve St Denis ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel S","family":"Slama","sequence":"additional","affiliation":[{"name":"Reference Center for Cardiac Amyloidosis, Cardiology Department, APHP Bichat Hospital, CRMR NNERF , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Payot","sequence":"additional","affiliation":[{"name":"Cardiology Department, General Hospital Yves Le Foll , 10 Rue Marcel Proust, 22000 Saint-Brieuc ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7571-9349","authenticated-orcid":false,"given":"Mohamad","family":"El Kasty","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Cardiologie, Grand H\u00f4pital de l'Est Francilien site Marne-La-Vall\u00e9e , Marne-la-Vall\u00e9e ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Aacha","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re (AP-HP), ACTION Study Group, INSERM UMRS 1166, Institut de Cardiologie, 83 blvd de l'H\u00f4pital, 75013 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdourahmane","family":"Diallo","sequence":"additional","affiliation":[{"name":"Unit\u00e9 de Recherche Clinique Lariboisi\u00e8re St Louis, ACTION Group, H\u00f4pital St-Louis & Fernand Widal , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Girerd","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re (AP-HP), ACTION Study Group, INSERM UMRS 1166, Institut de Cardiologie, 83 blvd de l'H\u00f4pital, 75013 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6303-8557","authenticated-orcid":false,"given":"Eric","family":"Vicaut","sequence":"additional","affiliation":[{"name":"Unit\u00e9 de Recherche Clinique Lariboisi\u00e8re St Louis, ACTION Group, H\u00f4pital St-Louis & Fernand Widal , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1901-2808","authenticated-orcid":false,"given":"Johanne","family":"Silvain","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re (AP-HP), ACTION Study Group, INSERM UMRS 1166, Institut de Cardiologie, 83 blvd de l'H\u00f4pital, 75013 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Montalescot","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re (AP-HP), ACTION Study Group, INSERM UMRS 1166, Institut de Cardiologie, 83 blvd de l'H\u00f4pital, 75013 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"key":"2025080106271869500_ehaf170-B1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/ehjcvp\/pvy034","article-title":"Effect of oral \u03b2-blocker treatment on mortality in contemporary post-myocardial infarction patients: a systematic review and meta-analysis","volume":"5","author":"Dahl Aarvik","year":"2019","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2025080106271869500_ehaf170-B2","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.jacc.2015.07.018","article-title":"Long-term use of cardiovascular drugs: challenges for research and for patient care","volume":"66","author":"Rossello","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2025080106271869500_ehaf170-B3","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.1093\/eurheartj\/ehaa376","article-title":"Long-term \u03b2-blocker therapy and clinical outcomes after acute myocardial infarction in patients without heart failure: nationwide cohort study","volume":"41","author":"Kim","year":"2020","journal-title":"Eur Heart J"},{"key":"2025080106271869500_ehaf170-B4","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1016\/j.jacc.2017.03.578","article-title":"\u03b2-blockers and mortality after acute myocardial infarction in patients without heart failure or ventricular dysfunction","volume":"69","author":"Dondo","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2025080106271869500_ehaf170-B5","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"2025080106271869500_ehaf170-B6","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.atherosclerosis.2010.02.017","article-title":"Heart rate as an independent prognostic risk factor in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention","volume":"211","author":"Parodi","year":"2010","journal-title":"Atherosclerosis"},{"key":"2025080106271869500_ehaf170-B7","doi-asserted-by":"publisher","first-page":"3500","DOI":"10.1016\/j.ijcard.2013.04.206","article-title":"Heart rate is a prognostic risk factor for myocardial infarction: a post hoc analysis in the PERFORM (Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack) study population","volume":"168","author":"Fox","year":"2013","journal-title":"Int J Cardiol"},{"key":"2025080106271869500_ehaf170-B8","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1016\/S0140-6736(16)31326-5","article-title":"Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study","volume":"388","author":"Vidal-Petiot","year":"2016","journal-title":"Lancet"},{"key":"2025080106271869500_ehaf170-B9","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1093\/ajh\/hps119","article-title":"Double product reflects the predictive power of systolic pressure in the general population: evidence from 9,937 participants","volume":"26","author":"Schutte","year":"2013","journal-title":"Am J Hypertens"},{"key":"2025080106271869500_ehaf170-B10","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"2025080106271869500_ehaf170-B11","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"2020 international society of hypertension global hypertension practice guidelines","volume":"75","author":"Unger","year":"2020","journal-title":"Hypertension"},{"key":"2025080106271869500_ehaf170-B12","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"2025080106271869500_ehaf170-B13","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1097\/01.hjh.0000249685.58370.28","article-title":"How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis","volume":"24","author":"Bradley","year":"2006","journal-title":"J Hypertens"},{"key":"2025080106271869500_ehaf170-B14","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","article-title":"Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial","volume":"366","author":"Dahl\u00f6f","year":"2005","journal-title":"Lancet"},{"key":"2025080106271869500_ehaf170-B15","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/S0140-6736(05)67573-3","article-title":"Should \u03b2 blockers remain first choice in the treatment of primary hypertension? A meta-analysis","volume":"366","author":"Lindholm","year":"2005","journal-title":"Lancet"},{"key":"2025080106271869500_ehaf170-B16","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1016\/S0140-6736(23)01733-6","article-title":"\u0392 blockers switched to first-line therapy in hypertension","volume":"402","author":"Messerli","year":"2023","journal-title":"Lancet"},{"key":"2025080106271869500_ehaf170-B17","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC Guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"2025080106271869500_ehaf170-B18","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa2404204","article-title":"Beta-blocker interruption or continuation after myocardial infarction","volume":"391","author":"Silvain","year":"2024","journal-title":"N Engl J Med"},{"key":"2025080106271869500_ehaf170-B19","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ahj.2023.01.014","article-title":"\u0392eta blocker interruption after uncomplicated myocardial infarction: rationale and design of the randomized ABYSS trial","volume":"258","author":"Silvain","year":"2023","journal-title":"Am Heart J"},{"key":"2025080106271869500_ehaf170-B20","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"key":"2025080106271869500_ehaf170-B21","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/S0140-6736(21)00590-0","article-title":"Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis","volume":"397","author":"Blood Pressure Lowering Treatment Trialists' Collaboration","year":"2021","journal-title":"Lancet"},{"key":"2025080106271869500_ehaf170-B22","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0140-6736(24)01028-6","article-title":"Lowering systolic blood pressure to less than 120\u2005mm Hg versus less than 140\u2005mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial","volume":"404","author":"Liu","year":"2024","journal-title":"Lancet"},{"key":"2025080106271869500_ehaf170-B23","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1056\/NEJMoa2401479","article-title":"Beta-blockers after myocardial infarction and preserved ejection fraction","volume":"390","author":"Yndigegn","year":"2024","journal-title":"N Engl J Med"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/46\/29\/2894\/63184583\/ehaf170.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/46\/29\/2894\/63184583\/ehaf170.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T10:27:23Z","timestamp":1754044043000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/46\/29\/2894\/8131812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":23,"journal-issue":{"issue":"29","published-online":{"date-parts":[[2025,5,22]]},"published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehaf170","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8,1]]},"published":{"date-parts":[[2025,5,22]]}}}